Skip Navigation

A PHASE III STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06246916

Study #:
STUDY00161102

Start Date:
Feb 21, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06246916

View Complete Trial Details & Eligibility at ClinicalTrials.gov